{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T17:47:22Z","timestamp":1743097642847,"version":"3.40.3"},"publisher-location":"Cham","reference-count":119,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783319571911"},{"type":"electronic","value":"9783319571935"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-3-319-57193-5_7","type":"book-chapter","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T05:03:24Z","timestamp":1499058204000},"page":"191-210","source":"Crossref","is-referenced-by-count":2,"title":["Motoneuron Disease: Clinical"],"prefix":"10.1007","author":[{"given":"Hristelina","family":"Ilieva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Maragakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,4]]},"reference":[{"issue":"Suppl 7","key":"7_CR1","first-page":"1","volume":"63","author":"P Mehta","year":"2014","unstructured":"Mehta P et al (2014) Prevalence of amyotrophic lateral sclerosis\u2013United States, 2010\u20132011. MMWR Surveill Summ 63(Suppl 7):1\u201314","journal-title":"MMWR Surveill Summ"},{"key":"7_CR2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jnnp.2009.183525","volume":"81","author":"G Logroscino","year":"2010","unstructured":"Logroscino G et al (2010) Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 81:385\u2013390","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7_CR3","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/17482960802566824","volume":"10","author":"A Chio","year":"2009","unstructured":"Chio A et al (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10:310\u2013323","journal-title":"Amyotroph Lateral Scler"},{"issue":"Suppl","key":"7_CR4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0022-510X(94)90191-0","volume":"124","author":"BR Brooks","year":"1994","unstructured":"Brooks BR (1994) El Escorial world federation of neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases\/amyotrophic lateral sclerosis of the world federation of neurology research group on neuromuscular diseases and the El Escorial \u201cclinical limits of amyotrophic lateral sclerosis\u201d workshop contributors. J Neurol Sci 124(Suppl):96\u2013107","journal-title":"J Neurol Sci"},{"key":"7_CR5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"BR Brooks","year":"2000","unstructured":"Brooks BR et al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293\u2013299","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"issue":"5\u20136","key":"7_CR6","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/21678421.2015.1049183","volume":"16","author":"A Ludolph","year":"2015","unstructured":"Ludolph A et al (2015) A revision of the El Escorial criteria\u20132015. Amyotroph Lateral Scler Frontotemporal Degener 16(5\u20136):291\u2013292","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"Suppl 1","key":"7_CR7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/21678421.2013.778548","volume":"14","author":"J Ravits","year":"2013","unstructured":"Ravits J et\u00a0al (2013) Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener 14(Suppl 1):5\u201318","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"7_CR8","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1212\/WNL.53.5.1071","volume":"53","author":"JS Katz","year":"1999","unstructured":"Katz JS et al (1999) Brachial amyotrophic diplegia: a slowly progressive motor neuron disorder. Neurology 53:1071\u20131076","journal-title":"Neurology"},{"key":"7_CR9","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1212\/01.wnl.0000345041.83406.a2","volume":"72","author":"LC Wijesekera","year":"2009","unstructured":"Wijesekera LC et al (2009) Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 72:1087\u20131094","journal-title":"Neurology"},{"key":"7_CR10","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/jnnp.2010.235952","volume":"82","author":"A Chio","year":"2011","unstructured":"Chio A et al (2011) Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 82:740\u2013746","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7_CR11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/jnnp.2006.103564","volume":"78","author":"CL Shoesmith","year":"2007","unstructured":"Shoesmith CL et al (2007) Prognosis of amyotrophic lateral sclerosis with respiratory onset. J Neurol Neurosurg Psychiatry 78:629\u2013631","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7_CR12","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1212\/WNL.0b013e3181c1dea3","volume":"73","author":"WK Kim","year":"2009","unstructured":"Kim WK et al (2009) Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology 73:1686\u20131692","journal-title":"Neurology"},{"key":"7_CR13","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/archneur.64.4.522","volume":"64","author":"J Visser","year":"2007","unstructured":"Visser J et\u00a0al (2007) Disease course and prognostic factors of progressive muscular atrophy. Arch Neurol 64:522\u2013528","journal-title":"Arch Neurol"},{"key":"7_CR14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1212\/01.wnl.0000200962.94777.71","volume":"66","author":"PH Gordon","year":"2006","unstructured":"Gordon PH et al (2006) The natural history of primary lateral sclerosis. Neurology 66:647\u2013653","journal-title":"Neurology"},{"key":"7_CR15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mus.20728","volume":"35","author":"MA Singer","year":"2007","unstructured":"Singer MA et al (2007) Primary lateral sclerosis. Muscle Nerve 35:291\u2013302","journal-title":"Muscle Nerve"},{"key":"7_CR16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/archneur.64.2.232","volume":"64","author":"MC Tartaglia","year":"2007","unstructured":"Tartaglia MC et al (2007) Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up. Arch Neurol 64:232\u2013236","journal-title":"Arch Neurol"},{"key":"7_CR17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/jnnp.61.5.450","volume":"61","author":"PJ Massman","year":"1996","unstructured":"Massman PJ et al (1996) Prevalence and correlates of neuropsychological deficits in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 61:450\u2013455","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7_CR18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1212\/01.wnl.0000172911.39167.b6","volume":"65","author":"GM Ringholz","year":"2005","unstructured":"Ringholz GM et al (2005) Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 65:586\u2013590","journal-title":"Neurology"},{"key":"7_CR19","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1212\/WNL.59.7.1077","volume":"59","author":"C Lomen-Hoerth","year":"2002","unstructured":"Lomen-Hoerth C et al (2002) The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 59:1077\u20131079","journal-title":"Neurology"},{"key":"7_CR20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/nyas.12638","volume":"1338","author":"AS Ng","year":"2015","unstructured":"Ng AS et al (2015) Frontotemporal dementia: a bridge between dementia and neuromuscular disease. Ann N Y Acad Sci 1338:71\u201393","journal-title":"Ann N Y Acad Sci"},{"key":"7_CR21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","volume":"72","author":"M DeJesus-Hernandez","year":"2011","unstructured":"DeJesus-Hernandez M et al (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72:245\u2013256","journal-title":"Neuron"},{"key":"7_CR22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neuron.2011.09.010","volume":"72","author":"AE Renton","year":"2011","unstructured":"Renton AE et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257\u2013268","journal-title":"Neuron"},{"key":"7_CR23","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/brain\/awr365","volume":"135","author":"J Cooper-Knock","year":"2012","unstructured":"Cooper-Knock J et\u00a0al (2012) Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 135:751\u2013764","journal-title":"Brain"},{"key":"7_CR24","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/jmedgenet-2011-100699","volume":"49","author":"S Millecamps","year":"2012","unstructured":"Millecamps S et al (2012) Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet 49:258\u2013263","journal-title":"J Med Genet"},{"key":"7_CR25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon G et al (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole study group [see comments]. N Engl J Med 330:585\u2013591","journal-title":"N Engl J Med"},{"key":"7_CR26","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","volume":"347","author":"L Lacomblez","year":"1996","unstructured":"Lacomblez L et al (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347:1425\u20131431","journal-title":"Lancet"},{"key":"7_CR27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1471-2377-13-84","volume":"13","author":"S Korner","year":"2013","unstructured":"Korner S et al (2013) Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options. BMC Neurol 13:84","journal-title":"BMC Neurol"},{"key":"7_CR28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000089626","volume":"2","author":"JC Desport","year":"2005","unstructured":"Desport JC et al (2005) Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2:202\u2013207","journal-title":"Neurodegener Dis"},{"key":"7_CR29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/WNL.53.5.1059","volume":"53","author":"JC Desport","year":"1999","unstructured":"Desport JC et al (1999) Nutritional status is a prognostic factor for survival in ALS patients. Neurology 53:1059\u20131063","journal-title":"Neurology"},{"key":"7_CR30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mus.22114","volume":"44","author":"S Paganoni","year":"2011","unstructured":"Paganoni S et al (2011) Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve 44:20\u201324","journal-title":"Muscle Nerve"},{"key":"7_CR31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1474-4422(10)70224-6","volume":"10","author":"L Dupuis","year":"2011","unstructured":"Dupuis L et al (2011) Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 10:75\u201382","journal-title":"Lancet Neurol"},{"key":"7_CR32","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3109\/21678421.2013.770028","volume":"14","author":"R Reich-Slotky","year":"2013","unstructured":"Reich-Slotky R et al (2013) Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener 14:212\u2013216","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"7_CR33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/21678421.2012.735240","volume":"14","author":"EJ O\u2019Reilly","year":"2013","unstructured":"O\u2019Reilly EJ et al (2013) Premorbid body mass index and risk of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 14:205\u2013211","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"7_CR34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1212\/WNL.0b013e3182840689","volume":"80","author":"V Gallo","year":"2013","unstructured":"Gallo V et al (2013) Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. Neurology 80:829\u2013838","journal-title":"Neurology"},{"key":"7_CR35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jns.2014.02.035","volume":"340","author":"ST Ngo","year":"2014","unstructured":"Ngo ST et al (2014) Body mass index and dietary intervention: implications for prognosis of amyotrophic lateral sclerosis. J Neurol Sci 340:5\u201312","journal-title":"J Neurol Sci"},{"key":"7_CR36","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/mus.24760","volume":"52","author":"S Paganoni","year":"2015","unstructured":"Paganoni S et al (2015) Reply: pre-morbid type 2 diabetes mellitus as a prognostic factor in ALS. Muscle Nerve 52:4. doi: 10.1002\/mus.24760","journal-title":"Muscle Nerve"},{"key":"7_CR37","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1212\/WNL.53.5.1123","volume":"53","author":"A Chio","year":"1999","unstructured":"Chio A et al (1999) Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. ALS percutaneous endoscopic gastrostomy study group. Neurology 53:1123\u20131125","journal-title":"Neurology"},{"key":"7_CR38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jns.2011.02.016","volume":"304","author":"R Spataro","year":"2011","unstructured":"Spataro R et al (2011) Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival. J Neurol Sci 304:44\u201348","journal-title":"J Neurol Sci"},{"key":"7_CR39","doi-asserted-by":"crossref","unstructured":"Langmore SE et al (2006) Enteral tube feeding for amyotrophic lateral sclerosis\/motor neuron disease. Cochrane Database Syst Rev:CD004030","DOI":"10.1002\/14651858.CD004030.pub2"},{"key":"7_CR40","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1212\/WNL.0b013e3181bc0141","volume":"73","author":"RG Miller","year":"2009","unstructured":"Miller RG et al (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1218\u20131226","journal-title":"Neurology"},{"key":"7_CR41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/17482960701656940","volume":"9","author":"P Corcia","year":"2008","unstructured":"Corcia P et al (2008) Causes of death in a post-mortem series of ALS patients. Amyotroph Lateral Scler 9:59\u201362","journal-title":"Amyotroph Lateral Scler"},{"key":"7_CR42","first-page":"643","volume":"119","author":"EH Bergofsky","year":"1979","unstructured":"Bergofsky EH (1979) Respiratory failure in disorders of the thoracic cage. Am Rev Respir Dis 119:643\u2013669","journal-title":"Am Rev Respir Dis"},{"key":"7_CR43","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0022-510X(99)00045-3","volume":"164","author":"KA Kleopa","year":"1999","unstructured":"Kleopa KA et al (1999) Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 164:82\u201388","journal-title":"J Neurol Sci"},{"key":"7_CR44","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1750-1172-4-10","volume":"4","author":"P Carratu","year":"2009","unstructured":"Carratu P et al (2009) Early treatment with noninvasive positive pressure ventilation prolongs survival in amyotrophic lateral sclerosis patients with nocturnal respiratory insufficiency. Orphanet J Rare Dis 4:10","journal-title":"Orphanet J Rare Dis"},{"key":"7_CR45","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1212\/01.WNL.0000076182.13137.38","volume":"61","author":"SC Bourke","year":"2003","unstructured":"Bourke SC et al (2003) Noninvasive ventilation in ALS: indications and effect on quality of life. Neurology 61:171\u2013177","journal-title":"Neurology"},{"key":"7_CR46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1474-4422(05)70326-4","volume":"5","author":"SC Bourke","year":"2006","unstructured":"Bourke SC et al (2006) Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 5:140\u2013147","journal-title":"Lancet Neurol"},{"key":"7_CR47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14660820310006706","volume":"4","author":"A Pinto","year":"2003","unstructured":"Pinto A et al (2003) Nocturnal pulse oximetry: a new approach to establish the appropriate time for non-invasive ventilation in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 4:31\u201335","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"7_CR48","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/(SICI)1097-4598(199908)22:8<1104::AID-MUS15>3.0.CO;2-2","volume":"22","author":"RG Miller","year":"1999","unstructured":"Miller RG et al (1999) Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Muscle Nerve 22:1104\u20131118","journal-title":"Muscle Nerve"},{"key":"7_CR49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1212\/01.WNL.0000069925.02052.1F","volume":"61","author":"H Hayashi","year":"2003","unstructured":"Hayashi H, Oppenheimer EA (2003) ALS patients on TPPV: totally locked-in state, neurologic findings and ethical implications. Neurology 61:135\u2013137","journal-title":"Neurology"},{"key":"7_CR50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/14660820500515021","volume":"7","author":"JG Rabkin","year":"2006","unstructured":"Rabkin JG et al (2006) Predictors and course of elective long-term mechanical ventilation: a prospective study of ALS patients. Amyotroph Lateral Scler 7:86\u201395","journal-title":"Amyotroph Lateral Scler"},{"key":"7_CR51","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1212\/WNL.43.2.438","volume":"43","author":"AH Moss","year":"1993","unstructured":"Moss AH et al (1993) Home ventilation for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family, and physician attitudes. Neurology 43:438\u2013443","journal-title":"Neurology"},{"key":"7_CR52","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1007\/s004150050641","volume":"245","author":"CD Borasio","year":"1998","unstructured":"Borasio CD et al (1998) Mechanical ventilation in amyotrophic lateral sclerosis: a cross-cultural perspective. J Neurol 245:S7\u2013S12","journal-title":"J Neurol"},{"key":"7_CR53","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.amjsurg.2008.11.008","volume":"197","author":"RP Onders","year":"2009","unstructured":"Onders RP et al (2009) Amyotrophic lateral sclerosis: the Midwestern surgical experience with the diaphragm pacing stimulation system shows that general anesthesia can be safely performed. Am J Surg 197:386\u2013390","journal-title":"Am J Surg"},{"key":"7_CR54","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1474-4422(15)00152-0","volume":"14","author":"DiPALS Writing Committee; DiPALS Study Group Collaborators","year":"2015","unstructured":"DiPALS Writing Committee; DiPALS Study Group Collaborators et al (2015) Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. Lancet Neurol 14:883\u2013892","journal-title":"Lancet Neurol"},{"key":"7_CR55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0022-510X(01)00610-4","volume":"191","author":"VE Drory","year":"2001","unstructured":"Drory VE et al (2001) The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 191:133\u2013137","journal-title":"J Neurol Sci"},{"key":"7_CR56","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/01.wnl.0000264418.92308.a4","volume":"68","author":"VD Bello-Haas","year":"2007","unstructured":"Bello-Haas VD et al (2007) A randomized controlled trial of resistance exercise in individuals with ALS. Neurology 68:2003\u20132007","journal-title":"Neurology"},{"key":"7_CR57","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1471-4159.2011.07224.x","volume":"117","author":"J Ganesalingam","year":"2011","unstructured":"Ganesalingam J et\u00a0al (2011) Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 117:528\u2013537","journal-title":"J Neurochem"},{"key":"7_CR58","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/j.1468-1331.2012.03777.x","volume":"19","author":"R Tortelli","year":"2012","unstructured":"Tortelli R et al (2012) Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 19:1561\u20131567","journal-title":"Eur J Neurol"},{"key":"7_CR59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3109\/21678421.2012.729596","volume":"14","author":"J Ganesalingam","year":"2013","unstructured":"Ganesalingam J et\u00a0al (2013) pNfH is a promising biomarker for ALS. Amyotroph Lateral Scler Frontotemporal Degener 14:146\u2013149","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"7_CR60","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3109\/21678421.2014.884592","volume":"15","author":"S Lehnert","year":"2014","unstructured":"Lehnert S et al (2014) Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 15:344\u2013350","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"7_CR61","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/j.1471-4159.2009.06386.x","volume":"111","author":"K Boylan","year":"2009","unstructured":"Boylan K et al (2009) Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem 111:1182\u20131191","journal-title":"J Neurochem"},{"key":"7_CR62","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.brainres.2014.10.031","volume":"1607","author":"N Bakkar","year":"2015","unstructured":"Bakkar N et al (2015) Use of biomarkers in ALS drug development and clinical trials. Brain Res 1607:94\u2013107","journal-title":"Brain Res"},{"key":"7_CR63","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.410230424","volume":"23","author":"DS Goodin","year":"1988","unstructured":"Goodin DS et al (1988) Magnetic resonance imaging in amyotrophic lateral sclerosis. Ann Neurol 23:418\u2013420","journal-title":"Ann Neurol"},{"key":"7_CR64","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3174\/ajnr.A0684","volume":"28","author":"DM Mezzapesa","year":"2007","unstructured":"Mezzapesa DM et al (2007) Whole-brain and regional brain atrophy in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol 28:255\u2013259","journal-title":"AJNR Am J Neuroradiol"},{"key":"7_CR65","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11910-015-0569-6","volume":"15","author":"MR Turner","year":"2015","unstructured":"Turner MR, Verstraete E (2015) What does imaging reveal about the pathology of amyotrophic lateral sclerosis? Curr Neurol Neurosci Rep 15:45","journal-title":"Curr Neurol Neurosci Rep"},{"key":"7_CR66","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/jnnp-2012-302674","volume":"84","author":"P Bede","year":"2013","unstructured":"Bede P et al (2013) Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry 84:766\u2013773","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7_CR67","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/brain\/awu162","volume":"137","author":"RA Menke","year":"2014","unstructured":"Menke RA et al (2014) Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain 137:2546\u20132555","journal-title":"Brain"},{"key":"7_CR68","doi-asserted-by":"crossref","unstructured":"Tan, R.H., et al. (2014) Cerebellar integrity in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One 9, e105632","DOI":"10.1371\/journal.pone.0105632"},{"key":"7_CR69","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.nicl.2015.01.009","volume":"7","author":"NR Zurcher","year":"2015","unstructured":"Zurcher NR et al (2015) Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. NeuroImage Clin 7:409\u2013414","journal-title":"NeuroImage Clin"},{"key":"7_CR70","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.nbd.2003.12.012","volume":"15","author":"MR Turner","year":"2004","unstructured":"Turner MR et al (2004) Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 15:601\u2013609","journal-title":"Neurobiol Dis"},{"issue":"Pt 11","key":"7_CR71","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1093\/brain\/123.11.2289","volume":"123","author":"CM Lloyd","year":"2000","unstructured":"Lloyd CM et al (2000) Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain J Neurol 123(Pt 11):2289\u20132296","journal-title":"Brain J Neurol"},{"key":"7_CR72","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.pscychresns.2007.07.003","volume":"156","author":"KL Lanctot","year":"2007","unstructured":"Lanctot KL et al (2007) Serotonin-1A receptors in frontotemporal dementia compared with controls. Psychiatry Res 156:247\u2013250","journal-title":"Psychiatry Res"},{"key":"7_CR73","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/brain\/awh428","volume":"128","author":"MR Turner","year":"2005","unstructured":"Turner MR et al (2005) [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain J Neurol 128:896\u2013905","journal-title":"Brain J Neurol"},{"key":"7_CR74","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archneur.1988.00520280027011","volume":"45","author":"SH Appel","year":"1988","unstructured":"Appel SH et al (1988) A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol 45:381\u2013386","journal-title":"Arch Neurol"},{"key":"7_CR75","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1017\/S031716710004734X","volume":"20","author":"A Eisen","year":"1993","unstructured":"Eisen A, Stewart H, Schulzer M, Cameron D (1993) Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine. Can J Neurol Sci 20:297\u2013301","journal-title":"Can J Neurol Sci"},{"key":"7_CR76","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ana.410350205","volume":"35","author":"DB Drachman","year":"1994","unstructured":"Drachman DB et al (1994) Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation [see comments]. Ann Neurol 35:142\u2013150","journal-title":"Ann Neurol"},{"key":"7_CR77","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/0022-510X(94)90188-0","volume":"124 Suppl","author":"SA Smith","year":"1994","unstructured":"Smith SA, Miller RG, Murphy JR, Ringel SP (1994) Treatment of ALS with high dose pulse cyclophosphamide. J Neurol Sci 124 Suppl:84\u201387","journal-title":"J Neurol Sci"},{"key":"7_CR78","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archneur.1995.00540300031009","volume":"52","author":"ES Louwerse","year":"1995","unstructured":"Louwerse ES, Weverling GJ, Bossuyt PM, Meyjes FE, de Jong JM (1995) Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 52:559\u2013564","journal-title":"Arch Neurol"},{"key":"7_CR79","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.410390215","volume":"39","author":"RG Miller","year":"1996","unstructured":"Miller RG et al (1996) A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 39:256\u2013260","journal-title":"Ann Neurol"},{"key":"7_CR80","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/mus.880190405","volume":"19","author":"RG Miller","year":"1996","unstructured":"Miller RG et al (1996) A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve 19:511\u2013515","journal-title":"Muscle Nerve"},{"key":"7_CR81","doi-asserted-by":"crossref","unstructured":"Miller, R. G. et al. Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul Disord 6, 101-104 (1996).","DOI":"10.1016\/0960-8966(95)00024-0"},{"key":"7_CR82","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.49.6.1621","volume":"49","author":"EC Lai","year":"1997","unstructured":"Lai EC et al (1997) Effect of recombinant human insulin-like growth factor-I on progression of ALS\u2014A placebo-controlled study. Neurology 49:1621\u20131630","journal-title":"Neurology"},{"key":"7_CR83","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1212\/WNL.51.2.583","volume":"51","author":"GD Borasio","year":"1998","unstructured":"Borasio GD et al (1998) A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS\/IGF-I Study Group. Neurology 51:583\u2013586","journal-title":"Neurology"},{"key":"7_CR84","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1212\/01.wnl.0000335970.78664.36","volume":"71","author":"EJ Sorenson","year":"2008","unstructured":"Sorenson EJ et al (2008) Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71:1770\u20131775. doi: 10.1212\/01.wnl.0000335970.78664.36","journal-title":"Neurology"},{"key":"7_CR85","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.1997.tb00231.x","volume":"96","author":"O Gredal","year":"1997","unstructured":"Gredal O et al (1997) A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Acta Neurol Scand 96:8\u201313","journal-title":"Acta Neurol Scand"},{"key":"7_CR86","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF02341783","volume":"19","author":"A Chio","year":"1998","unstructured":"Chio A, Cucatto A, Terreni AA, Schiffer D (1998) Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial. Ital J Neurol Sci 19:363\u2013366","journal-title":"Ital J Neurol Sci"},{"key":"7_CR87","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1212\/WNL.52.7.1427","volume":"52","author":"EJ Kasarskis","year":"1999","unstructured":"Kasarskis EJ et al (1999) A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 52:1427\u20131433","journal-title":"Neurology"},{"key":"7_CR88","doi-asserted-by":"crossref","first-page":"A469","DOI":"10.1212\/WNL.46.1.238","volume":"46","author":"RG Miller","year":"1996","unstructured":"Miller RG et al (1996) A placebo-controlled trial of gabapentin in amyotrophic lateral sclerosis. Neurology 46:A469","journal-title":"Neurology"},{"key":"7_CR89","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/146608201300079364","volume":"2","author":"C Desnuelle","year":"2001","unstructured":"Desnuelle C, Dib M, Garrel C, Favier AA (2001) double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2:9\u201318","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"7_CR90","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/WNL.61.4.456","volume":"61","author":"ME Cudkowicz","year":"2003","unstructured":"Cudkowicz ME et al (2003) A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology 61:456\u2013464","journal-title":"Neurology"},{"key":"7_CR91","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/ana.10554","volume":"53","author":"GJ Groeneveld","year":"2003","unstructured":"Groeneveld GJ et al (2003) A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 53:437\u2013445. doi: 10.1002\/ana.10554","journal-title":"Ann Neurol"},{"key":"7_CR92","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1212\/01.WNL.0000142992.81995.F0","volume":"63","author":"JM Shefner","year":"2004","unstructured":"Shefner JM et al (2004) A clinical trial of creatine in ALS. Neurology 63:1656\u20131661","journal-title":"Neurology"},{"key":"7_CR93","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14660820410019602","volume":"5","author":"V Meininger","year":"2004","unstructured":"Meininger V et al (2004) Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials. Amyotroph Lateral Scler Other Motor Neuron Disord 5:107\u2013117","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"7_CR94","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1212\/01.wnl.0000187070.35365.d7","volume":"65","author":"KL Ferrante","year":"2005","unstructured":"Ferrante KL et al (2005) Tolerance of high-dose (3,000 mg\/day) coenzyme Q10 in ALS. Neurology 65:1834\u20131836","journal-title":"Neurology"},{"key":"7_CR95","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.20903","volume":"60","author":"ME Cudkowicz","year":"2006","unstructured":"Cudkowicz ME et al (2006) Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 60:22\u201331","journal-title":"Ann Neurol"},{"key":"7_CR96","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/01.wnl.0000191326.40772.62","volume":"66","author":"V Meininger","year":"2006","unstructured":"Meininger V et al (2006) Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Neurology 66:88\u201392","journal-title":"Neurology"},{"key":"7_CR97","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","volume":"6","author":"PH Gordon","year":"2007","unstructured":"Gordon PH et al (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6:1045\u20131053","journal-title":"Lancet Neurol"},{"key":"7_CR98","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1212\/01.wnl.0000269676.07319.09","volume":"69","author":"R Miller","year":"2007","unstructured":"Miller R et al (2007) Phase II\/III randomized trial of TCH346 in patients with ALS. Neurology 69:776\u2013784","journal-title":"Neurology"},{"key":"7_CR99","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17482960802320487","volume":"10","author":"ME Cudkowicz","year":"2009","unstructured":"Cudkowicz ME et al (2009) Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler 10:99\u2013106","journal-title":"Amyotroph Lateral Scler"},{"key":"7_CR100","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3109\/17482960903307805","volume":"11","author":"RM Pascuzzi","year":"2010","unstructured":"Pascuzzi RM et al (2010) A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:266\u2013271. doi: 10.3109\/17482960903307805","journal-title":"Amyotroph Lateral Scler"},{"key":"7_CR101","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3109\/17482968.2010.498521","volume":"11","author":"M Carvalho de","year":"2010","unstructured":"de Carvalho M et al (2010) A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:456\u2013460. doi: 10.3109\/17482968.2010.498521","journal-title":"Amyotroph Lateral Scler"},{"key":"7_CR102","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1212\/WNL.0b013e31822dc7a5","volume":"77","author":"RG Miller","year":"2011","unstructured":"Miller RG et al (2011) Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology 77:973\u2013979. doi: 10.1212\/WNL.0b013e31822dc7a5","journal-title":"Neurology"},{"key":"7_CR103","doi-asserted-by":"publisher","unstructured":"Group, U. K.-L. S. et al. (2013) Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 12, 339\u2013345, doi: 10.1016\/S1474-4422(13)70037-1","DOI":"10.1016\/S1474-4422(13)70037-1"},{"key":"7_CR104","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S1474-4422(13)70221-7","volume":"12","author":"ME Cudkowicz","year":"2013","unstructured":"Cudkowicz ME et al (2013) Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 12:1059\u20131067. doi: 10.1016\/S1474-4422(13)70221-7","journal-title":"Lancet Neurol"},{"key":"7_CR105","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1474-4422(14)70222-4","volume":"13","author":"ME Cudkowicz","year":"2014","unstructured":"Cudkowicz ME et al (2014) Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol 13:1083\u20131091. doi: 10.1016\/S1474-4422(14)70222-4","journal-title":"Lancet Neurol"},{"key":"7_CR106","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1212\/NXI.0000000000000100","volume":"2","author":"RG Miller","year":"2015","unstructured":"Miller RG et al (2015) Randomized phase 2 trial of NP001-a novel immune regulator: safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm 2:e100. doi: 10.1212\/NXI.0000000000000100","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"7_CR107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2006.12.015","volume":"26","author":"M Benatar","year":"2007","unstructured":"Benatar M (2007) Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 26:1\u201313","journal-title":"Neurobiol Dis"},{"key":"7_CR108","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen DR et al (1993) Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59\u201362","journal-title":"Nature"},{"key":"7_CR109","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.4155\/cli.11.127","volume":"1","author":"JD Berry","year":"2011","unstructured":"Berry JD, Cudkowicz ME (2011) New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Investig 1:1375\u20131389","journal-title":"Clin Investig"},{"key":"7_CR110","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1126\/science.8209258","volume":"264","author":"ME Gurney","year":"1994","unstructured":"Gurney ME et al (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation [see comments]. Science 264:1772\u20131775","journal-title":"Science"},{"key":"7_CR111","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s13311-015-0344-z","volume":"12","author":"LV Reddy","year":"2015","unstructured":"Reddy LV, Miller TM (2015) RNA-targeted therapeutics for ALS. Neurotherapeutics 12:424\u2013427","journal-title":"Neurotherapeutics"},{"key":"7_CR112","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","volume":"11","author":"R Kole","year":"2012","unstructured":"Kole R et al (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11:125\u2013140","journal-title":"Nat Rev Drug Discov"},{"key":"7_CR113","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","volume":"116","author":"RA Smith","year":"2006","unstructured":"Smith RA et al (2006) Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 116:2290\u20132296","journal-title":"J Clin Invest"},{"key":"7_CR114","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller TM et al (2013) An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 12:435\u2013442","journal-title":"Lancet Neurol"},{"key":"7_CR115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.brainres.2014.09.017","volume":"1607","author":"JP Richard","year":"2015","unstructured":"Richard JP, Maragakis NJ (2015) Induced pluripotent stem cells from ALS patients for disease modeling. Brain Res 1607:15\u201325","journal-title":"Brain Res"},{"key":"7_CR116","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/stem.1079","volume":"30","author":"JD Glass","year":"2012","unstructured":"Glass JD et al (2012) Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells 30:1144\u20131151","journal-title":"Stem Cells"},{"key":"7_CR117","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ana.24113","volume":"75","author":"EL Feldman","year":"2014","unstructured":"Feldman EL et al (2014) Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol 75:363\u2013373","journal-title":"Ann Neurol"},{"key":"7_CR118","doi-asserted-by":"crossref","unstructured":"Lepore, A.C., et al. (2011) Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. PLoS One 6, e25968","DOI":"10.1371\/journal.pone.0025968"},{"key":"7_CR119","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/archneurol.2010.248","volume":"67","author":"D Karussis","year":"2010","unstructured":"Karussis D et al (2010) Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 67:1187\u20131194","journal-title":"Arch Neurol"}],"container-title":["Advances in Neurobiology","Neurodegenerative Diseases"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-57193-5_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T02:37:10Z","timestamp":1569638230000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-57193-5_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783319571911","9783319571935"],"references-count":119,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-57193-5_7","relation":{},"ISSN":["2190-5215","2190-5223"],"issn-type":[{"type":"print","value":"2190-5215"},{"type":"electronic","value":"2190-5223"}],"subject":[],"published":{"date-parts":[[2017]]}}}